Biotechnology company developing oral and intravenous therapies for rare and serious diseases.
BioCryst Pharmaceuticals, Inc., a prominent biotechnology company based in Durham, North Carolina, specializes in the discovery of novel oral small-molecule medicines. The company's product portfolio includes peramivir injection, an intravenous neuraminidase inhibitor marketed under the names RAPIVAB, RAPIACTA, and PERAMIFLU for the treatment of acute uncomplicated influenza. BioCryst also offers ORLADEYO, an oral serine protease inhibitor designed to manage hereditary angioedema.
Innovating beyond its current offerings, BioCryst Pharmaceuticals is actively developing BCX9930, an oral factor D inhibitor currently undergoing Phase II clinical trials for complement-mediated diseases. Additionally, the company is advancing BCX9250, an oral activin receptor-like kinase-2 inhibitor in Phase I trials aimed at treating fibrodysplasia ossificans progressiva. Another notable candidate in its pipeline is Galidesivir, a RNA-dependent RNA polymerase inhibitor currently in Phase I trials targeting various RNA viruses such as Marburg, Yellow Fever, Ebola, and Zika.
Since its inception in 1986, BioCryst Pharmaceuticals has established strategic collaborations and in-license relationships with key entities including Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Furthermore, the company collaborates closely with prominent research institutions such as the National Institute of Allergy and Infectious Diseases (NIAID), the Biomedical Advanced Research and Development Authority (BARDA), the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd.
Headquartered in the biotechnology hub of Durham, North Carolina, BioCryst Pharmaceuticals is strategically positioned to leverage the region's scientific talent and research infrastructure. The company remains dedicated to advancing its mission of pioneering innovative therapies that address significant unmet medical needs across infectious diseases and rare genetic conditions.